These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31599867)

  • 1. Duaklir Pressair: another LAMA/LABA inhaler for COPD.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):149-151. PubMed ID: 31599867
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison table: Inhaled long-acting bronchodilators for treatment of COPD.
    Med Lett Drugs Ther; 2020 Sep; 62(1606):e146-e147. PubMed ID: 32960874
    [No Abstract]   [Full Text] [Related]  

  • 3. Table: Correct Use of inhalers for COPD.
    Med Lett Drugs Ther; 2020 Sep; 62(1606):e150-e154. PubMed ID: 32960876
    [No Abstract]   [Full Text] [Related]  

  • 4. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for COPD.
    Med Lett Drugs Ther; 2020 Sep; 62(1606):137-144. PubMed ID: 32960872
    [No Abstract]   [Full Text] [Related]  

  • 6. Expanded table: Correct use of inhalers for asthma.
    Med Lett Drugs Ther; 2020 Dec; 62(1613):e204-e208. PubMed ID: 33446624
    [No Abstract]   [Full Text] [Related]  

  • 7. Revefenacin (Yupelri) for COPD.
    Med Lett Drugs Ther; 2019 Jan; 61(1564):14-15. PubMed ID: 30856160
    [No Abstract]   [Full Text] [Related]  

  • 8. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
    Rhee CK; Yoshisue H; Lad R
    Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebulized glycopyrrolate (Lonhala Magnair) for COPD.
    Med Lett Drugs Ther; 2018 Apr; 60(1543):72. PubMed ID: 29667949
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.
    Lee HW; Park J; Jang EJ; Lee CH
    Respir Res; 2020 Nov; 21(1):310. PubMed ID: 33238986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
    Rogliani P; Matera MG; Ritondo BL; De Guido I; Puxeddu E; Cazzola M; Calzetta L
    Pulm Pharmacol Ther; 2019 Dec; 59():101841. PubMed ID: 31520718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Duarte M; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1781-1795. PubMed ID: 35983168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seebri Neohaler and Utibron Neohaler for COPD.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():231-245. PubMed ID: 36908830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.
    Gong Y; Lv Y; Liu H; Zheng Q; Li L
    Ther Adv Respir Dis; 2022; 16():17534666211066068. PubMed ID: 35001708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.
    Ramadan WH; Al Masri S; Rizk J
    Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.